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Summary
In the present study we demonstrate that human monocytes activated by lipopolysaccharides 
(LPS) were able to produce high levels of interleukin 10 (IL-10), previously designated cytokine 
synthesis inhibitory factor (CSIF), in a dose dependent fashion. IL-10 was detectable 7 h after 
activation of the monocytes and maximal levels o f IL-10 production were observed after 24-48 h. 
These kinetics indicated that the production of IL-10 by human monocytes was relatively late 
as compared to the production of IL-la, IL-ljS, IL-6 , IL-8 , tumor necrosis factor o:{TNFa), and 
granulocyte colony-stimulating factor (G-CSF), which were all secreted at high levels 4-8  h after 
activation. The production of IL-10 by LPS activated monocytes was, similar to that of IL-la, 
IL-1/3, IL-6, IL-8 , TNFo, granulocyte-macrophage colony-stimulating factor (GM-CSF), and G-CSF, 
inhibited by IL-4. Furthermore we demonstrate here that IL-10, added to monocytes, activated 
by interferon 7 (IFN-7 ), LPS, or combinations of LPS and IFN -7  the onset of the cultures, 
strongly inhibited the production of IL-lce, IL-lß, IL-6 , IL-8 , TN Fa, GM-CSF, and G-CSF at 
the transcriptional level. Viral-IL-10, which has similar biological activities on human cells, also 
inhibited the production of T N F a and GM-CSF by monocytes following LPS activation. Activation 
of monocytes by LPS in the presence of neutralizing anti-IL-10 monoclonal antibodies resulted 
in the production of higher amounts of cytokines relative to LPS treatment alone, indicating 
that endogenously produced IL-10 inhibited the production of IL-la, IL-ljS, IL-6 , IL-8 , TNFo:, 
GM-CSF, and G-CSF. In addition, IL-10 had autoregulatory effects since it strongly inhibited 
IL-10 mRNA synthesis in LPS activated monocytes. Furthermore, endogenously produced IL-10 
was found to be responsible for the reduction in class II major histocompatibility complex (MHC) 
expression following activation of monocytes w ith LPS. Taken together our results indicate that 
IL-10 has important regulatory effects on immunological and inflammatory responses because 
of its capacity to downregulate class II M HC expression and to inhibit the production of 
proinflammatory cytokines by monocytes.
Murine-IL-10 was recently identified and its gene cloned based on its cytokine synthesis inhibitory (CSIF)1 ac­
tivity (1, 2). In murine systems, IL-10 was produced by the 
C D 4+ Th2 subset and inhibits the cytokine production, 
particularly IFN-7 , by Thl clones (1, 2). The inhibition of 
cytokine production by IL-10 was observed only when mac­
rophages, but not when B cells were used as APCs (3). In 
addition to its CSIF activity, IL-10 was shown to be pleiotropic 
and to act on different cell types, including thymocytes (4),
1 Abbreviations used in this paper: CSIF, cytokine synthesis inhibitory factor; 
G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte- 
macrophage colony-stimulating factor; v-IL-10, viral-IL-10.
cytotoxic T cells (5), mast cells (6), B cells (7), and macro­
phages (3).
Human IL-10 also exhibits CSIF activity (8 ). We have 
demonstrated that the production of IFN -7  and granulocyte- 
macrophage colony-stimulating factor (GM-CSF) by PBMC  
activated by PH A or anti-CD 3 mAbs was strongly inhibited 
by IL-10 and that this inhibition occurred at the transcrip­
tional level (8 ). Both human and murine IL-10 have extensive 
sequence homology to a previously uncharacterized open 
reading frame in the Epstein Barr virus genome, BCRF-1 
(2 , 8). Expression o f the open reading frame yielded an ac­
tive protein, designated viral-IL-10 (v-IL-10), which shared 
most properties with human and murine IL-10, including CSIF 
activity on mouse and human T cells (9).
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Recently, we described that human IL-10 and v-IL-10 were 
able to inhibit antigen specific proliferative T cell responses 
by reducing the antigen presenting capacity of human mono­
cytes via downregulation of class II MHC molecules (9a). 
Here we describe that human monocytes were able to pro­
duce high levels of IL-10 following activation with LPS and 
that this production was relatively late as compared to that 
of other monokines. In addition, it is reported here that IL-10 
strongly inhibited the production of the proinflammatory
cytokines IL-lo:, IL-ljS, IL-6 , IL-8 , and T N Fa and the hae­
matopoietic growth factors GM-CSF and granulocyte colony- 
stimulating factor (G-CSF) by monocytes activated by LPS, 
IFN-y, or LPS and IFN-y. Endogenously produced IL-10 
had not only autoregulatory effects on IL-la, IL-ljS, IL-6 , 
IL-8, TNFa, GM-CSF, and G-CSF production by monocytes, 
but also downregulated its own production and class II MHC 
expression on monocytes in an autoregulatory fashion. These 
results indicate that IL-10 has important regulatory effects 
on immunological and inflammatory responses.
Materials and Methods
Isolation and Culture o f Human Monocytes. Human PB Ms were 
isolated from 500 ml blood of normal donors as described previ­
ously (10,11). Mononuclear cells were isolated by density centrifu­
gation in a blood component separator, followed by fractionation 
into lymphocytes and monocytes by centrifugal élutriation. The 
monocyte preparation was >95% pure, as judged by nonspecific 
esterase staining and contained more than 98% viable cells. Mono­
cytes were cultured in YssePs medium (12) containing HSA sup­
plemented with 1% pooled heat inactivated human AB + serum. 
This culture medium was endotoxin free as determined by the 
Limulus amebocyte lysate assay (<0.2 ng/ml of endotoxin). The 
monocytes were cultured at a concentration of 4 x 106 cells/ml 
in teflon bags (Jansen MNL, St. Niklaas, Belgium), which prevented 
adhesion of these cells. After culture for the times indicated, mono­
cytes were collected and analyzed for cell surface expression by in­
direct immunofluorescence or analyzed for lymphokine gene ex­
pression by Northern and PCR analysis. In addition, monocyte 
culture supernatants were collected for determination of IL-la, IL-ljS, 
IL-6, IL-8, IL-10, TNFa, GM-CSF, and G-CSF production following 
activation of these cells. The viability of the cells after culture always 
exceeded 95% as determined by trypan blue exclusion.
Reagents. Recombinant human IL10 and v-IL-10 were expressed 
in Escherichia coli as glutathione-S-transfera se fusion proteins, 
purified, and digested with thrombin to remove the N-terminal 
fusion part (13), resulting in active human and v-IL-10 as described 
previously (9a). Purified human rIL-4 and rlFN-y were provided 
by Schering-Plough Research (Bloomfield, NJ). LPS (E. coli 0127:B8) 
was obtained from Difco Laboratories (Detroit, MI), The neu­
tralizing anti-IL-10 mAb 19F1 was raised against v-IL-10 and 
efficiently neutralized both, human and viral-IL-10 (Silver, J., and 
J. Abrams, manuscript in preparation).
Proles, The following probes were used for northern analysis:
600 bp Sma I fragment (nt 1299 - 1899) of'pCD-hTGFjS (14), 1200 
bp Pst I fragment ofpAL (0-actin) (8), 567 bp BamHI-Xba I frag­
ment (nt 1 - 567) of pCD-hIL-6 (14), 268 bp Hind III fragment 
(nt 29 - 297) of SP64-3-10c (IL-8) (15), 760 bp Bgl II - Hind III 
fragment (nt 159 - 919) of pCD-SRa-hlLlO (8). The following 
oligonucleotides were used for Southern analysis of PCR products:
IL-la: 5'-CATGGGTGCTTATAAGTCATC-3' (nt 500-521) (16);
IL-ljS: 5'-CGATCACTGAACTGCACGCTCCGGG-3' (nt 444 - 
469) (16); IL-6: 5'GAGGTAIACCTAGAGTACCTC-3' (nt 510 - 531)
(17); IL-8: 5 '-TA AAGACATACTCCAAACCTT-3' (nt 200 - 221) 
(15); IL-10: 5'-CAGGTGAAGAATGCCTTTAATAAGCTCCAA- 
GAGAAAGGCATCTACAAAGCCATGAGTGAGTTTGACATC- 
3' (nt 429 - 498) (8); TNFa: 5-GGCGTGGAGCTGAGAGATAAC- 
3' (nt 500 - 521) (18); GM-CSF: 5'-CCGGCGTCTCCTGAACCT-3' 
(nt 150 - 168) (19); actin: 5'-CTGAACCCTAAGGCCAACCGTG- 
3' (nt 250 - 272) (20); and G-CSF: 5'-GCCCTGGAAGGGATC- 
TCCCCC-3' (nt 400 - 421) (21).
m R N A  Isolation and Northern Analysis, Total RNA was iso­
lated from 20 x 106 monocytes by the guanidinium thiocyanate- 
CsCl procedure (22). For northern analysis, 10 fig  total R N A  per 
sample was separated according to size on 1% agarose gels con­
taining 6.6% formaldehyde, transferred to Nytran nylon membranes 
(Schleicher & Schuell, Keene, NH) and hybridized with probes, 
labeled to high specific activity (>108 cpm//ig) by the hexamer 
labeling technique (23). Filters were hybridized, washed under strin­
gent conditions, and developed as previously described (24).
Polymerase Chain Reaction (P C R ) Analysis. 1 j ig  of total RNA  
was reverse transcribed using oligo (dT) 12-18 as primer (Boehringer 
Mannheim, Indianapolis, IN) and AMV reverse transcriptase 
(Boehringer Mannheim) according to the procedure of Krug and 
Berger (25) in a 20 jA reaction. 2 jA of reverse transcript (equivalent 
to 100 ng of total RNA) was used directly for each amplification 
reaction. Conditions for PCR were as follows: in a 50 fil reaction, 
25 nmol of each primer, 125 juM each of dGTP, dATP, dCTP and 
dTTP (Pharmacia, Uppsala, Sweden), 50 mM KCl, 10 mM Tris- 
HC1, pH 8.3, 1.5 mM MgCb, 1 mg/ml gelatin, 100 /Ag/ml non­
ace tyla ted BSA and 1 U Vent D N A  polymerase (New England Bio- 
labs, Beverly, MA). Primers used were as follows: IL-la sense primer
5'-CATCGCCAATGACTCAGAGGAAG-3' (nt 302-325), IL-la 
antisense primer 5 '-TGCCAAGCACACCCAGTAGTCTTGCTT-3' 
(nt 770 - 743) (16), IL-ljS sense primer 5'-CCAGCTACGAAT- 
CTCGGACCACC-3' (nt 230 - 253), IL-ljS anti sense primer 
5*-TTAGGAAGACACAAATTGCAIGGTGAAGTCAGT-3' (nt 896
- 863) (16), IL-6 sense primer S'-ATGAACTCCTTCTCCACA- 
AGC-3' (nt 1 - 21), TL-6 anti sense primer 5'-CTACATTTGCC- 
GAAGAGCCCTCAGGCTGGACTG-3 ' (nt 810 - 777) (17), IL-8 
sense primer 5'-ATGACTTCCAAGCTGGCCGTG-3' (nt 1 - 21), 
11-8 anti sense primer 5' -TTATGA ATTCTC AGCCCTCTTC A A- 
AAACTTCTC-3' (nt 302 - 269) (15), IL-10 sense primer 5'-ATG- 
CCCC AAGCTGAGA ACC A AGACCC A-3 ' (nt 323 - 349), IL-10 
anti sense primer 5'-TCTCAAGGGGCTGGGTCAGCTATCC- 
CA-3' (nt 674 - 648) (8), T N F a sense primer 5'-AGAGGGA- 
AGAGTTCCCCAGGGAC-3 ' (nt 310 - 333), TNFa anti sense 
primer 5'-TGAGTCGGTCACCCTTCTCCAG-3' (nt 782 - 760)
(18), GM-CSF sense primer 5'-GCATCTCTGCACCCGCCCG- 
CTCGCC-3' (nt 76-100), GM-CSF anti sense primer 5'-CCTGC- 
TTGTACAGCTCCAGGCGGGT-3' (nt 276 - 250) (19), G-CSF 
sense primer 5'-GAGTGTGCCACCTACAAGCTGTGCC-3' (nt 
233 - 258), G-CSF anti sense primer 5'-CCTGGGTGGGCTG- 
CAGGGCAGGGGC-3' (nt 533 - 508) (21), j3-actin sense primer 
5'-GTGGGGCGCCCCAGGCACCA-3' (nt 1 - 20), 0-actin anti 
sense primer 5'-GTCCTTAATGTCACGCACGATTTC-3' (nt 548
- 530) (20). Reactions were incubated in a Perkin-Elmer/Cetus DNA  
Thermal cycler for 20 cycles (dénaturation 30 s 94°C, annealing 
30 s 55 °C, extension 60 s 72° C). Reactions were extracted with 
CHCI3 and 40 pt\ per sample was loaded on 1% agarose gels in 
TAE buffer. Products were visualized by ethidium bromide staining. 
Subsequently, gels were denatured in 0.5 M NaOH, 1.5 M NaCl, 
neutralized in 10 M ammonium acetate, and transferred to Nytran 
nylon membranes. Membranes were pre-hybridized in 6 x SSC,
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Figure 1. The kinetics of IL-10, IL-6, TNFa; and GM-CSF production by human monocytes, activated by LPS. Human monocytes, isolated by cen­
trifugal élutriation were cultured in teflon bags (4 x 106/ml) in the absence or presence of LPS (1 fxg/ml) and production of ( / )  IL-10, (B) IL-6, 
(C) T N F a  and (D) GM-CSF was determined in the culture supernatants harvested at the times indicated by cytokine specific ELISA’s.
V
1% SDS, 10 x Denhardt’s solution (0.2% Ficoll, 0.2% polyvinyl­
pyrrolidone, 0.2% BSA, pen tax fraction V) and 200 /xg/ml & coli 
tR N A  (Boehringer, Mannheim, FRG) for 4 h at 55 °C. Oligonu­
cleotide probes (200 ng), specific for a sequence internal to the 
primers used in the amplification, were labeled at the 5' end by 
T4 polynucleotide kinase (New England Biolabs) and 7 -32P-ATP 
(Amersham, Arlington Heights, IL) as described (26). Probes were 
separated from nonincorporated nucleotides by passage over a Nick 
column (Pharmacia) and added to the hybridization mix. Following
hybridization for 12 h  at 55°C, filters were washed in 0.1 x SSC 
(1 x SSC:150 mM NaCl, 15 mM Na-citrate pH -  7.0), 1% SDS 
at room temperature and exposed to Kodak XAR-5 films for 1-2 h, 
Lymphokine Determinations. The production of IL-la and TNFa  
by monocytes was measured by lymphokine specific ELISA’s ob­
tained from Endogen (Boston, MA). The lower detection limit 
of these ELISA’s were 50 pg/ml and 10 pg/ml respectively. Produc­
tion of IL-1/3 was determined by lymphokine specific ELISA ob­
tained from Cistron (Pine Brook, NJ). The sensitivity of this ELISA
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was 20 pg/ml. IL-6 levels were determined by lymphokine specific 
ELISA purchased from Genzyme (Boston, MA). The sensitivity 
of this assay was 0.313 ng/ml. IL-8 and G-CSF specific ELISA’s 
were obtained from R&D Systems (Minneapolis, MN) and used 
to quantitate IL-8 and G-CSF production. The sensitivity of these 
ELISA’s was 4.7 pg/ml and 7.2 pg/ml respectively. GM-CSF produc­
tion was determined by lymphokine specific ELISA as described 
previously (27). The sensitivity of this ELISA was 50 pg/ml. IL-10 
production was determined by a specific ELISA in which the anti-IL- 
10 mAb JES 9D7 was used as a coating antibody and the anti-IL-10 
mAb JES342G8 as a tracer antibody (Silver, J., and J. Abrams, 
manuscript in preparation). The sensitivity of this ELISA was 50 
pg/ml.
Immunofluorescence Analysis. Cells (105) were incubated in V 
bottom microtiter plates (Flow Laboratories, McLean, VA) with 
10 fi 1 of purified mAb (1 mg/ml) for 30 min at 4°C. After two 
washes with PBS containing 0.02 mM sodium azide and 1% BSA 
(Sigma Chemical Co., St. Louis, MO), the cells were incubated 
with 1/40 dilution of FITC labeled F(ab')2 fragments of goat 
anti-mouse antibody (Tago, Inc., Burlingame, CA) for 30 min at 
4°C. After three additional washes, the labeled cell samples were 
analyzed by flow microfluometry on a FACScan (Becton Dickinson 
and Co., Sunnyvale, CA). The anti-MHC class II mAbs PdV5.2 
(HLA-DR/DP/DQ) (28), Q5/13 HLA-DR/DP (29), and L243 
(HLA-DR) (30) were described previously.
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Figure 2. The production of IL-10 by human monocytes in response 
to increasing concentrations of LPS. Human monocytes (4 x 106/ml) 
were cultured in teflon bags with increasing concentrations of LPS for 
24 h and the production of IL-10 was determined by ELISA.
Results
IL-10 Is Produced by Human Monocytes. We have shown 
previously that IL-10 was produced by activated human T 
cell clones, activated peripheral blood T and B cells, EBV 
transformed B cell lines (8) and monocytes (Abrams, J., H. 
Yssel, and M. G. Roncarolo, manuscript in preparation). Here 
we further characterize IL-10 production by human mono­
cytes. Highly-purified human monocytes, isolated by cen-
produced rapidly upon activated and reached maximal levels 
of production at 3.5 and 7.5 h following activation respec­
tively (Fig. 1). However, GM-CSF production was also first 
detected 7.5 b after activation of monocytes by LPS, but in 
this case maximal production levels were reached at 20  h. 
Dose response studies indicated that activation of monocytes 
by LPS at 10 ng/m l already resulted in significant levels of
trifugal élutriation, produced IL-10 following activation by IL-10 production, whereas the maximal IL-10 synthesis was
LPS. In addition, it is shown that these human monocytes 
were able to produce high levels of IL-6 , T N Fa, and GM- 
CSF (Fig. 1). Kinetics of cytokine production by LPS acti­
vated monocytes indicated that IL-10 production by mono­
cytes was relatively late. It was first detected in supernatants 
harvested at 7.5 h, but maximal production was observed 
20-48 h after activation. In contrast, TNFo: and IL-6 were
observed at LPS concentrations of 1 ptg/ml (Fig. 2).
ILÎ0 Inhibits Cytokine Production by Human Monocytes, IL-10 
has been shown to inhibit IFN-7  and GM-CSF production 
by activated PBMC (8). To determine the effects of IL-10 on 
the production of cytokines by monocytes, highly-purified, 
monocytes were activated for 24 h by LPS in the absence or 
presence of IL-10. In addition, monocytes were activated w ith
Table 1. Effects o f Exogenous IL-10, Endogenous IL-10, and IL-4 on Cytokine Production by Human Monocytes
IL -la IL-ljS IL-6 IL-8 IL-10 T N Fa
1
GM-CSF G-CSF
Medium 37°C 0 0 0 150
ng/m l
0 0 0 0
LPS 1.2 44.8 261.7 479 30.6 21.2 0.6 90
LPS + IL-4 0 9.7 135.7 418 11.9 5.1 0 17.5
LPS + IL-10 0 13.6 78 434 N D 2.6 0 21.1
LPS + aIL-10 2.7 50.6 323 672 N D 47.6 5.5 110
Human monocytes, isolated by centrifugal élutriation were cultured in teflon bags at a concentration of 4 x 106 cells/ml and activated by LPS (1 
/ig/ml) in the absence and presence of IL-10 (100 U /m l), IL-4 (100 U /m l) or anti-IL-10 mAb 19F1 (10 /xg/ml) for 24 h and production of cytokines 
was determined in the supernatants by cytokine specific ELISA’s. ND: not done.
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Figure 3. The effects of IL-10 on the production of cytokines by mono­
cytes activated by IFN-y, LPS or LPS and IFN-y* Human monocytes (4 
x 10ö/ml) were cultured with IFN-y (100 U/ml), 1, 10, 100, or 1,000 
ng/ml LPS and combinations of LPS (1, 10, 100, or 1,000 ng/ml) and 
IFN-y (100 U/ml) either in the absence (□ )  or presence (ffl) of IL10 (100 
U/ml) for 24 h and production of (A) IL-lce, (.B) IL-lß, (C) IL-6, (D) TNFa, 
and (£) GM-CSF was determined by cytokine specific ELISA’s in the su­
pernatants.
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LPS for 24 h in the presence of IL-4 (100 U/ml) or neutralizing 
anti-IL-10 mAb 19F1, which was raised against v-IL-10 but 
efficiently neutralized both human IL-10 and v-IL-10 (Silver, 
J., and J. Abrams, manuscript in preparation) (The latter results 
are discussed below). Cytokine production was determined 
in the supernatants of these cultures, harvested 24 h after ac­
tivation, by cytokine specific ELISA’s. As shown in shown 
in Table 1, monocytes which were incubated in medium alone
at 37°C did not produce IL-la, IL-1/3, IL-6 , IL-10, T N Fa,
GM-CSF, and G-CSF. Under these conditions, only significant 
levels of IL-8 were synthesized. Activation of monocytes with 
LPS (1 fig /ml) resulted in production of high levels of IL-la,
IL-1/3, IL-6 , IL-8 , IL-10, TNFa, GM-CSF, and G-CSF. In­
terestingly, IL-10 inhibited the production of IL-la, IL-1/3, 
IL-6 , IL-8 , TN Fa, GM-CSF, and G-CSF to various extents 
(Table 1). The strongest inhibitory effects of IL-10 were ob­
served on the production of IL-la, T N Fa, GM-CSF, and 
G-CSF, which were blocked by 80-100%. The inhibition of 
IL-lß and IL-6 production was less pronounced, whereas the 
synthesis of IL-8 was only slightly affected by IL-10.
ILIO A  Iso Inhibits Cytokine Production o f Monocytes Activated 
by IF N -y . IL-10 also inhibited cytokine production by mono­
cytes activated by IFN-7 , or combinations of IFN-y and LPS. 
In Fig. 3, it is shown that IFN-y at optimal concentrations 
of 100 U /m l generally was a less potent inducer of cytokine 
secretion than was LPS at optimal concentrations of 1 fig/m l. 
Furthermore, it is demonstrated that the effects of combina­
tions of IFN-y and LPS on cytokine production by mono­
cytes generally were additive. The strongest inhibitory effects 
of IL-10 were observed on IL-la, TNFa and GM-CSF produc­
tion. T N F a and GM-CSF secretion was suppressed by more 
than 90%, even following activation of the monocytes by 
optimal LPS and IFN-y concentrations. Although consider­
able inhibitory effects on IL-ljS and IL-6 secretion were ob­
served at optimal stimulation conditions, their inhibition was 
more pronounced when the monocytes were stimulated by 
suboptimal concentrations of LPS, either in the absence or 
presence of optimal concentrations of IFN-y.
Viral ILIO Inhibits Cytokine Production by Monocytes.
IL-10 and human IL-10 have similar effects on human cells 
(9). In Fig. 4, it is shown that both IL-10 and v-IL-10 in­
hibited T N F a  and GM-CSF production by monocytes in a 
similar fashion. IL-10 and v-IL-10, added at concentrations 
of 100 U/m l, had significant inhibitory effects on TN Fa and 
GM-CSF production by monocytes following activation by 
LPS (1 fig /m l). These inhibitory effects of IL-10 and v-IL-10 
on T N F-a and GM-CSF secretion were reversed when incu­
bations were carried out in the presence of mAb 19F1 (Fig. 
4), demonstrating the specificity of the inhibitory effects of 
v-IL-10. In fact, activation of monocytes by LPS in the pres­
ence of IL-10 or v-IL-10 and the neutralizing anti-IL-10 mAb 
resulted even in enhanced production of TNFa and GM-CSF, 
indicating that endogenously produced IL-10 suppressed the 
production o f these cytokines.
Endogenously Produced IL10 Inhibits Cytokine Production by 
Monocytes. The inhibitory effects of endogenously produced 
IL-10 on cytokine production by monocytes was further evalu-
6 0 -
Viral
50-
4 0 "
ULzH
30 -
20-
10-
0
antl-IL-10
B
LUif)0
1
2O
10-
0
f<v«v\y«v*v/«V
f / /  f c o : o :o ' . o x c d
/ / /  U 'O I 7 .V. Y , . ,S #11111 jpüp piifl
✓ y y  y . ' - y w  a v « v , 
/ / a  $  < < < ' \ Y y * ' ' / y y%ip§
# »  
VV
antM L -10
Figure 4. The effects of human IL-10 and viral-IL-10 on the production 
of TNFa: and GM-CSF by LPS activated monocytes. Human monocytes 
(4 x 106/ml) were activated by LPS (1 /ig/ml) and cultured with human 
IL--10 (100 U/ml) or viral-IL10 in the absence or in the presence of neu­
tralizing anti-IL-10 mAb 19F1 (10 fig /ml) for 24 h and production of (A) 
T N F a  and (B) GM-CSF was determined by cytokine specific ELISA’s.
a ted by quantifying cytokine levels produced by LPS activated 
monocytes in the presence of neutralizing anti-IL-10 mAb. 
In Table 1 it is shown that LPS plus anti-IL-10 treatment 
of monocytes resulted in higher levels of cytokine produc­
tion as compared to activation by LPS alone, indicating that 
endogenously produced IL-10 in addition to its inhibitory 
effects on T N Fa and GM-CSF production blocked the produc­
tion of IL-la, ILrl/3, IL-6 , IL8 , and G-CSF. The most sig­
nificant inhibitory effects were found on the production of 
IL-la, GM-CSF, and TN Fa, whereas the inhibitory effects 
on IL-1/3, IL-6 , IL-8 , and G-CSF expression were consider­
able, but less pronounced. Taken together these results indi­
cate that both exogenous IL-10 and endogenously produced
IL-10 inhibit the production o f IL-la, IL-1/3, IL-6 , IL-8 , TNFa, 
GM-CSF, and G-CSF by LPS activated monocytes.
IL 4  Inhibits IL10 Production by Activated Monocytes. We 
demonstrated previously that IL-4 inhibited production of 
IL-ljS, IL-6 , and T N F a by LPS activated monocytes (31). To 
determine whether IL-4 also inhibited IL-10 production, mono­
cytes were activated by LPS for 24 h and IL-10 secretion was 
measured. As shown in Table 1, IL-4 strongly inhibited IL10 
production by LPS activated monocytes. Furthermore, IL-4,
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Figure 6. The effects o f IL-10 on the expression of cytokine specific 
mRNA levels by human monocytes activated by LPS. mRNA was iso­
lated from human monocytes (4 x 106/ml), activated by LPS (1 ftg/ml) 
in the absence or presence of IL-10 (100 U/ml) for 7 h and expression of 
IL-6, IL-8, IL-10, TGF-/3, and ß actin was determined by northern analyses.
F ig u r e  5 .  The effects of exogenous IL-10, endogenously produced ILIO 
a n d  ILr4 o n  the expression of cytokine specific mRNA levels by human 
m o n o c y t e s  activated by LPS. Human monocytes (4 x 106/ml) were cul­
t u r e d  i n  m edium  at 4°C and 37°C or activated by LPS (1 mg/ml) in the 
a b se n c e  o r  presence of IL-4 (100 U/ml), IL-10 (100 U/ml) and neutralizing 
a n t i- IL -1 0  m Ab 19F1 (10 /xg/ml) and mRNA was isolated after 24 h. Ex­
p re s s io n  o f  jS-actin, IL-la, IL-ljS, IL6, IL-8, TN F-a, GM-CSF and G-CSF 
w a s  d e te rm in ed  on reverse transcribed mRNA by PCR analyses with 
c y to k in e  specific primers followed by Southern blotting of the reaction 
p ro d u c ts  w ith  internal probes. cDNA obtained from a CD4+ T cell clone 
w a s  in c lu d ed  as control for expression of T N F a and GM-CSF.
in  addition to its inhibitory effects on IL-1/3, IL-6 , and TNFa  
secretion , efficiently blocked the production of GM-CSF and 
G -C SF . However, as observed for IL-10, the production of 
IL-8  w as only slightly affected by IL-4. Collectively these data 
ind icate that IL-4 and IL-10 have comparable inhibitory effects 
o f  cytokine production by activated monocytes.
Inhibition of Monokine Production Occurs at the Transcriptional 
Level To determine at which level IL-10 inhibited the produc­
tion of cytokines by monocytes, comparative PCR analyses 
were performed on R N A  isolated from monocytes, activated 
by LPS in the absence or presence of IL-10, IL-4 or the neu­
tralizing anti-IL-10 mAb for 24 h. The cytokine measure­
ments of this experiment are shown in Table 1. mRNA iso­
lated from these samples was reverse transcribed into cDNA  
and subsequently amplified with cytokine specific primers, 
A relatively small number of cycles was used for amplification 
to ensure that the amount of amplified DNA was propor­
tional to the cycle number and correlated with the amount 
of specific mRNA in the original sample. It is shown in Fig. 
5 that under these conditions equivalent amounts of jS-actin 
specific cDNA were amplified. Monocytes incubated at 4°C  
in medium alone for 24 h expressed very low levels of IL-8 
mRNA. Incubation of these cells at 37°C resulted in an in-
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Figure 7. The effects of exogenous IL-10, en­
dogenously produced IL-10 and IL-4 on the ex­
pression of IL-10 and TGF/3 specific mRNA 
levels by human monocytes activated by LPS. 
Human monocytes (4 x 106/ml) were cul­
tured in medium at 4°C and 37°C or activated 
by LPS (1 mg/ml) in the absence or presence
of IL-4 (100 U/ml), IL-10 (100 U/ml) and neu­
tralizing anti-IL-10 mAb 19F1 (10 ^g/ml) and 
mRNA was isolated after 24 h. Expression of 
(A) IL-10, TGFß and /3-actin was determined 
by northern analyses and (B) expression of IL­
IO was determined on reverse transcribed 
mRNA by PCR analysis with cytokine specific 
primers followed by Southern blotting of the 
reaction products with internal probes.
creased expression of IL-8 mRNA, but did not induce ex­
pression of IL-la, IL-1/3, IL-6 , IL-10, TN Fa, GM-CSF, or
G-CSF mRNA. LPS activation resulted in a strong expres­
sion of IL-la, IL-1/3, IL-6 , IL-8 , and G-CSF m RNA, whereas 
T N Fa and GM-CSF mRNA were moderately induced. Fur­
thermore, it is shown in Fig. 5 that IL-la, IL-6 , TNFa, GM- 
CSF, and G-CSF expression was strongly inhibited by IL-10 
and IL-4 at the mRNA level (Fig. 5), whereas IL-1/3 and IL-8 
expression were only slightly affected by IL-10. Activation 
of monocytes by LPS in the presence of the anti-IL-10 mAb 
resulted in a moderate enhancement in expression of IL-la, 
IL-1/3, IL-6 , IL-8 , and G-CSF mRNA and a strong increase 
in T N F a and GM-CSF mRNA synthesis. The levels of ex­
pression of cytokine specific mRNA and their modulation 
by exogenous and endogenous IL-10 or IL-4 correlated well 
with secretion of the corresponding proteins as shown in Table
1 and indicated that IL-10 and IL-4 inhibited cytokine expres­
sion by LPS activated monocytes at the transcriptional level.
IL-10 Regulates IL-10 m R N A  but not TG Fß m R N A  E x­
pression in Activated Monocytes. Having demonstrated that
human monocytes produced IL-10 relatively late following 
activation by LPS, we determined, whether IL-10 could affect 
endogenous IL-10 mRNA synthesis. Human monocytes were 
activated by LPS in the presence or absence of IL-10 for 7 h 
and m R N A  expression was analyzed by northern blotting. 
In Fig. 6 it is shown that IL-10 mRNA was detected 7 h 
after activation by LPS and that IL-10 had no or only min­
imal inhibitory effects on IL-10 mRNA expression at this time 
point. In contrast, the expression of IL-6 and IL-8 m RNA  
was strongly inhibited by IL-10. However, in another series 
of experiments where monocytes were activated for 24 h by 
LPS, IL-10 strongly reduced the expression of IL-10 m RNA  
as shown by northern analysis in Fig. 7. Furthermore, it is 
shown in Fig. 7 that activation of monocytes with LPS in 
the presence of a neutralizing anti-IL-10 mAb resulted in an 
upregulation of IL-10 mRNA expression at 24 h. These results 
were confirmed by PCR analysis with IL-10 specific primers 
since the R N A  used in this latter experiment was also used 
for the PCR analyses shown in Fig. 5. It is shown in Fig. 7 
B that the quantitative differences observed in IL-10 m RNA
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expression by Northern analysis correlated with those ob­
served by comparative PCR analysis. In addition, the more 
sensitive PCR analysis allowed the detection of low levels 
of IL-10 mRNA that were induced 24 h after culture of mono­
cytes in medium alone at 37 °C. These results indicate that 
IL-10 has autoregulatory effects on IL-10 mRNA synthesis 
and if mRNA levels accurately reflect IL-10 protein produc­
tion, probably on IL-10 production by human monocytes as 
well. However, downregulation of IL-10 production occurred 
rather late in the activation process. TGF/3 mRNA, which 
was expressed constitutively in freshly isolated non activated 
monocytes, was not enhanced by LPS activation for 7 or 24 h 
(Pigs. 6 and 7). In addition, it is shown in Figs. 6 and 7 that 
the levels of TGF/3 m RNA were not affected when activa­
tions were carried out in the presence of IL-4, IL-10, or neu­
tralizing anti-IL-10 mAbs.
ILIO Has Autoregulatory Effects on Class II M HC Expres­
sion by Monocytes. Recently, we demonstrated that IL-10 
downregulated the expression of class II MHC molecules on 
the cell surface of human monocytes (9a). IL-10 was shown 
to downregulate constitutive, IL-4 or IFN-7 -induced MHC 
class II expression. Since monocytes produce high levels of 
IL-10 following activation by LPS, the possibility that en­
dogenous IL-10 could inhibit class II MHC expression by LPS 
activated monocytes was investigated. Monocytes were acti­
vated by various concentrations of LPS in the presence or 
absence of the neutralizing anti-IL-10 mAb. In Fig. 8 it is 
shown that activation of monocytes with LPS reduced the 
constitutive H LA-DR/DP expression on these cells in a dose 
dependent manner. However, in the presence of the neu­
tralizing anti-IL-10 mAb 19F1 strong induction of HLA- 
D R /D P  expression was observed. Identical results were ob­
tained with several HLA-DR or HLA-DR/DP specific mAb. 
These results indicate that endogenously produced IL-10, in 
an autoregulatory fashion, was responsible for the downregu­
lation of class II M HC expression on human monocytes fol­
lowing LPS activation.
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Figure 8. T he effects of endogenously produced ILrlO on class II MHC 
expression by human monocytes, activated w ith  LPS. Human monocytes 
were cultured w ith (yl) 0 ng/ml LPS, (B) 0.1 ng/ml LPS, (O) 10 ng/ml
LPS, o r (D) 1,000 ng/ml LPS in the absence or presence of neutralizing 
anti-IL-10 m Ab 19F1 (10 mg/ml) for 40 h and expression of HLA-DR/DP
(Q5/13) was determined by indirect immunofluorescence.
Discussion
In the present study we demonstrated that human IL-10 
was produced in relatively large quantities by monocytes fol­
lowing activation. Kinetic studies showed that low levels of 
IL-10 could be detected 7 h after activation of the monocytes, 
and maximal IL-10 production occurred 24-48 h after activa­
tion. This was relatively late as compared to the production
of IL-la, IL-1/3, IL-6 , IL-8 and T N F -a, which were secreted 
at high levels between 4-8 h after activation (31-33). In ad­
dition, we showed that human IL-10 has strong inhibitory 
effects on cytokine production by monocytes following acti­
vation with IFN-7 , LPS or combinations of IFN-Y and LPS. 
These inhibitory effects are specific for IL-10 since they could 
be completely neutralized by mAb 19F1 which inhibits both 
IL-10 and v-IL-10 activity. IL 10 added at concentrations of 
100 U/m l reduced IL-la, TNF-a, GM-CSF, and G-CSF syn­
thesis by more than 90% following optimal activation of the 
monocytes by combinations of IFN -7  (100 U/ml) and LPS 
(1 fig/m l). The inhibitory effects on IL-1/3, IL-6 , and IL-8
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production were somewhat less pronounced, particularly when 
the monocytes were optimally activated by combinations of 
IFN-y and LPS. The mechanism by which IL-10 inhibits 
cytokine production by monocytes is not clear. It remains 
to be determined whether these effects of IL-10 are direct or 
indirectly mediated via other factors. Since IL-1 can induce 
IL-6 production in fibroblasts, thymocytes, and monocytes 
(34-36), it is, for example, possible that the partial inhibi­
tion of IL6 production is the result of reduced IL1 production.
Viral-ILIO which has been shown to possess biological 
activities, on human cells similar to human IL-10 (9), was 
less extensively tested. However, v-IL-10 inhibited T N Fa and 
GM-CSF production by LPS activated monocytes to the same 
extent as did human IL-10. These inhibitory effects of v-IL-
10 on T N F a and GM-CSF production were neutralized by 
mAb 19F1, illustrating the specificity of the v-IL-10 effects.
Inhibition of IL-la, IL-1/3, IL-6 , IL-8 , T N F -a, GM-CSF,
and G-CSF secretion occurred at the transcriptional level. IL-10 
strongly inhibited cytokine specific m RNA synthesis induced 
by LPS, as determined by northern and PCR analyses. PCR  
analyses were performed under conditions that allowed a com­
parison of the reaction products of individual samples in a 
semiquantitative manner. This was validated by the fact that 
amplification of cDNA’s with primers specific for /3-actin 
resulted in equivalent amounts of reaction products between 
the samples and quantitatively comparable results were ob­
tained when IL-10 m RNA expression was determined in the 
same samples by both northern and PCR analysis. In addi­
tion, cytokine mRNA expression levels correlated with the 
protein levels in the supernatants of these cultures. ILIO failed 
to affect TGF-/3 mRNA expression in activated monocytes. 
However, it has to be noted here that TGF-/3 was constitu- 
tively expressed in nonactivated monocytes and that activa­
tion of the monocytes by LPS did not affect TGF-/3 m R N A  
levels. Assoian et al. (37) have demonstrated that monocytes 
constitutively express TGF-/3 mRNA and that TGF-/3 secre­
tion requires monocyte activation. However, it remains to 
be determined whether IL-10 has an effect on the conversion 
of TGF-/3 from its latent to its active form.
The production of IL-10 was shown to be inhibited by IL-4 
at the transcriptional level. Although the inhibitory effects 
of IL-4 on IL-10 production were considerable, IL-4 was not 
able to block the production of ILIO completely. IL-4 inhibited 
the production of IL-10 only up to 70%, even when high 
IL-4 concentrations (400 U/ml), which were sufficient to com­
pletely inhibit the production of IL-1, IL-6 , and TN Fa, were 
used (results not shown). We (31) and others (38-40) have 
demonstrated previously that IL-4 was able to inhibit the
production of IL-la, IL-1/3, IL6 , IL-8 (41), and T N F a by
human monocytes. These findings were confirmed here and 
extended by demonstrating that IL-4 also inhibited the produc­
tion of IL8 , GM-CSF, and G-CSF by LPS activated human 
monocytes. This inhibition occurred at the transcriptional 
level. The data furthermore illustrate that IL-4 and IL-10 have 
similar effects on cytokine expression by human monocytes, 
which underlines the pleio tropic effects of cytokines and redun­
dancy in the immune system.
Interestingly, IL-10 is an autoregulatory cytokine, since it 
strongly inhibited IL-10 mRNA synthesis in monocytes acti­
vated for 24 h. In addition, activation of monocytes by LPS 
in the presence of neutralizing anti-IL-10 mAbs resulted in 
an increased expression of IL-10 mRNA at 24 h, indicating 
that endogenously produced IL-10 also inhibited IL-10 mRNA  
synthesis. The fact that IL-10 is able to downregulate its own 
production by human monocytes makes this the first cytokine 
that is regulated by a negative feedback mechanism. Au­
toregulatory effects of endogenously produced IL-10 were also 
observed on the production of IL-la, IL-ljS, IL-6 , IL-8 , TNF-a, 
GM-CSF, and G-CSF by LPS activated monocytes. However, 
the inhibitory effects of endogenous IL-10 on the production 
of these cytokines were less pronounced than those of exoge­
nous IL-10 added at the onset of the culture. This is related
to the fact that IL-la, IL-1/3, IL-6 , IL-8 , TNF-a, and G-CSF
are already produced at high levels 4-8 h after activation, 
whereas maximal endogenous IL-10 production occurs much 
later at 24-48 h after activation. This notion is supported 
by the observation that the strongest inhibitory effects of en­
dogenously produced IL-10 were found on GM-CSF secre­
tion which was shown to be produced late following activa­
tion of the monocytes. Assuming that IL-10 mRNA synthesis 
reflects and precedes IL-10 protein secretion, and that IL-10 
can only interact with its receptor on the cell surface, these 
results suggest that the inhibitory effects of endogenously 
produced IL-10 occur relatively late and may therefore be of 
particular importance in the later phases of an immune re­
sponse.
IL-10 was first described in the mouse as a CSIF produced 
by Th2 cells, which inhibited cytokine production (pre­
dominately IF N -y  by Thl cells (1). This inhibitory effect of 
mouse-IL-10 on cytokine production by Thl cells required 
the presence of macrophages (3). Recently we demonstrated 
that human IL-10 and v-IL-10 strongly inhibited antigen 
specific T cell proliferation when monocytes were used as 
APC (9a). In addition, it was shown that reduction in the 
antigen specific proliferative T cell responses were for a major 
part due to the reduced antigen presenting capacity of the 
monocytes caused by strong downregulatory effects of IL-10 
on class II M HC antigen expression on these cells. These 
data, together with the present finding that IL-10 is produced 
late by monocytes and has autoregulatory effects on IL-10 secre­
tion by these cells, indicate that IL-10 may have strong down- 
regulatory effects on ongoing antigen specific T cell responses. 
Therefore IL-10 may be a cytokine that plays a major role 
in dampening antigen driven proliferative T cell responses, 
The notion, that IL-10 produced by monocytes may also have 
strong autoregulatory feedback activity on T cell activation, 
is supported by the observation that IL-10 produced by mono­
cytes following activation by LPS is responsible for down- 
regulation of class II MHC antigens on these cells, since class
II M HC expression was not reduced and even strongly en­
hanced when LPS stimulations were carried out in the pres­
ence of the neutralizing anti-IL-10 mAb.
The finding that IL-10 has strong downregulatory effects 
on the secretion of the pro inflammatory cytokines IL-la, IL
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1/3, ILr6 , IL-8 , and TN F-a which are all involved in acute
and chronic inflammatory processes, many autoimmune dis­
eases, including rheumatoid arthritis and not only modulate 
the activation and function of cells of the immune system 
but also those of endothelial cells, keratinocytes and hepato- 
cytes (42-44), suggests that IL-10 is a powerful inhibitor of 
inflammation. Based on its properties described thus far, which
include inhibition of antigen specific T cell proliferation by 
reducing the APC capacity of monocytes through downregu- 
lation of class II MHC antigens on these cells and inhibitory 
effects on proinflammatory cytokine secretion by monocytes, 
it seems that IL-10 plays a major role as a suppressor of im­
mune and inflammatory responses.
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